60 Degrees Pharmaceuticals, Inc.
SXTP
$1.41
$0.118.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 126.18% | 115.43% | 164.39% | 123.55% | 9.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 126.18% | 115.43% | 164.39% | 123.55% | 9.35% |
| Cost of Revenue | -78.05% | 323.02% | 441.63% | 241.06% | 242.59% |
| Gross Profit | 105.20% | -474.02% | -611.54% | -262.93% | -378.08% |
| SG&A Expenses | 17.48% | 24.09% | 18.46% | 78.62% | 165.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.40% | 87.46% | 92.24% | 141.04% | 209.27% |
| Operating Income | 13.83% | -85.60% | -88.68% | -141.92% | -239.10% |
| Income Before Tax | -383.21% | -1,201.94% | -108.61% | -131.35% | 82.14% |
| Income Tax Expenses | 100.00% | -25.00% | -25.00% | -- | 250.00% |
| Earnings from Continuing Operations | -383.14% | -1,201.65% | -108.60% | -131.37% | 82.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -86.13% | -87.01% | -82.12% | 338.64% | 1,969.57% |
| Net Income | -397.33% | -1,294.74% | -111.03% | -130.84% | 82.65% |
| EBIT | 13.83% | -85.60% | -88.68% | -141.92% | -239.10% |
| EBITDA | 14.16% | -86.05% | -89.55% | -143.81% | -243.18% |
| EPS Basic | -327.84% | 49.58% | 79.57% | 69.08% | 101.86% |
| Normalized Basic EPS | 83.29% | 68.84% | 83.52% | 75.63% | 71.56% |
| EPS Diluted | -327.84% | 49.58% | 79.57% | 69.08% | 101.86% |
| Normalized Diluted EPS | 83.29% | 68.84% | 83.52% | 75.63% | 71.56% |
| Average Basic Shares Outstanding | 652.29% | 642.00% | 586.39% | 361.62% | 254.31% |
| Average Diluted Shares Outstanding | 652.29% | 642.00% | 586.39% | 361.62% | 254.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |